Drug Overview

Odetiglucan (brand name Imprime PGG) is an investigational, systemically administered immune modulator. It is a soluble polysaccharide—specifically a β-1,3/1,6 glucan—derived from the cell wall of a proprietary strain of the yeast Saccharomyces cerevisiae. Classified as a Pathogen-Associated Molecular Pattern (PAMP), it is designed to mimic a fungal threat to “prime” and activate the body’s innate immune system to recognize and attack cancer.

In the clinical landscape of March 2026, odetiglucan is being developed by HiberCell. It is recognized for its unique ability to “reprogram” the tumor microenvironment (TME). By shifting immunosuppressive cells (like M2 macrophages) into a pro-inflammatory state (M1), odetiglucan removes the “protective shield” that tumors use to hide from the immune system. It is primarily studied in combination with immune checkpoint inhibitors (like pembrolizumab) and other targeted therapies to enhance their effectiveness in “cold” or resistant tumors.

Generic Name: Odetiglucan.
Brand Name: Imprime PGG.
Code Names: BTH1677, BTH-1677.
Drug Class: Pathogen-Associated Molecular Pattern (PAMP); β-Glucan; Immunostimulant.
Mechanism: Activation of innate immune cells (neutrophils, monocytes, macrophages) via CR3, Dectin-1, and Fc\gammaRIIA receptors.
Route of Administration: Intravenous (IV) infusion.
FDA Approval Status: Investigational. As of March 2026, odetiglucan is not FDA-approved. It is currently in Phase 2 clinical trials for several indications.

What Is It and How Does It Work? (Mechanism of Action)

Odetiglucan acts as a “molecular bridge” that links the innate and adaptive immune systems.

1. Immune Complex Formation

Once injected into the bloodstream, odetiglucan binds to naturally occurring anti-beta glucan antibodies (ABA) and is opsonized with complement proteins (C3). This creates an immune complex.

2. Receptor Agonism

The odetiglucan immune complex targets and binds to three specific receptors on innate immune cells (neutrophils, monocytes, and macrophages):

Complement Receptor 3 (CR3): The primary binding site.
Dectin-1: A classic beta-glucan receptor.
Fc\gammaRIIA (CD32A): Helps in cell activation and antibody-dependent cellular cytotoxicity (ADCC).

3. Reprogramming the Tumor Microenvironment (TME)

M1/M2 Shift: It converts immunosuppressive “M2” macrophages (which help tumors grow) into pro-inflammatory “M1” macrophages (which kill tumors).
T-Cell Expansion: By activating antigen-presenting cells (APCs), it facilitates the expansion of CD4+ and CD8+ T-cells, essentially turning a “cold” tumor (unresponsive to immune attack) into a “hot” one.

Clinical Indications and Status (2026)

Odetiglucan is being evaluated in several high-need oncology settings:

Metastatic Triple-Negative Breast Cancer (mTNBC): Currently in Phase 2 trials in combination with pembrolizumab. Early data has shown encouraging median overall survival (mOS) and disease control rates (DCR).
Hormone-Refractory Breast Cancer: Evaluated in a Phase 2 study for patients who have progressed through prior hormone therapy and CDK4/6 inhibitors.
Pancreatic Duct Adenocarcinoma (PDAC): A recent trial (IGNITE trial, Oct 2025) is exploring odetiglucan in combination with an agonistic CD40 antibody as a second-line therapy.
Liver Metastases: Being studied in Phase 1/2 trials to determine if it can reprogram the unique immune environment of the liver to allow better tumor destruction.
Non-Small Cell Lung Cancer (NSCLC): Previously studied in combination with pembrolizumab; results indicated the combination was safe but showed limited additional benefit in patients who had already failed prior immunotherapy.

Dosage and Administration Protocols

As an investigational agent, dosing is strictly regulated within clinical trial protocols.

Parameter	Clinical Specification (2026)
Standard Dose	4 mg/kg (sometimes reduced to 2 mg/kg in dose-escalation phases).
Route	Intravenous (IV) infusion.
Infusion Time	Typically administered over 2 hours.
Frequency	Often given on Days 1, 8, and 15 of a 21-day treatment cycle.
Combination Timing	Usually administered before the immune checkpoint inhibitor (e.g., pembrolizumab).

Safety Profile and Side Effects

Odetiglucan is generally well-tolerated, particularly because it focuses on activating specific immune cells rather than causing a generalized “cytokine storm.”

Common Side Effects (>15%):

Infusion-Related Reactions: Fever, chills, and mild flushing during or shortly after the IV drip.
Fatigue: General systemic tiredness.
Gastrointestinal: Mild nausea or abdominal discomfort.
Skin Rash: Occasional itching or redness.

Serious Risks:

Hypersensitivity: Rare cases of severe allergic reactions (anaphylaxis) to the yeast-derived polysaccharide.
Lipase Elevation: Transient increases in lipase levels have been noted in some gastrointestinal tumor trials.
Immune-Mediated Events: When used with pembrolizumab, the risk of typical checkpoint inhibitor side effects (like pneumonitis or colitis) remains and must be monitored.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, odetiglucan is used to study “Trained Immunity.” Researchers are investigating how exposure to beta-glucans can “program” hematopoietic stem cells in the bone marrow to produce more “aggressive” anti-tumor myeloid cells. In 2026, there is also intense focus on “Liver-Specific Immunomodulation,” with scientists using odetiglucan to understand why the liver is so often a “safe haven” for metastatic cancer and how to “wake up” the liver’s resident immune cells (Kupffer cells) to attack tumors.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

Anti-Beta Glucan Antibody (ABA) Testing: Since the drug requires these antibodies to form an immune complex, some trials screen patients for baseline ABA levels.
Baseline Blood Work: Comprehensive CBC and metabolic panel (especially liver enzymes and lipase).

“Do’s and Don’ts” List:

DO expect to stay in the clinic for an extra hour after your first few infusions to monitor for any infusion-related reactions.
DO report any “shaking chills” or high fever during the infusion; the nursing team can slow the drip or give medications like acetaminophen to help.
DON’T ignore sudden stomach pain or nausea, as these could be signs of elevated pancreatic enzymes.
DON’T take any new over-the-counter “immune boosting” mushroom supplements (which also contain beta-glucans) without consulting your oncologist, as they may interfere with the study drug’s dosing.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Odetiglucan (Imprime PGG) is an investigational agent and is not approved by the U.S. FDA for commercial use. Access is restricted exclusively to registered clinical trials. Always consult with a qualified oncologist or clinical investigator regarding your specific diagnosis and eligibility for research participation.